A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
Latest Information Update: 13 Jul 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-671
- Sponsors Merck Sharp & Dohme Corp.
- 04 Jun 2024 Results assessing Health-related quality of life (HRQoL) outcomes, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 15 May 2024 According to a Merck & Co media release, data from this trial will be presented will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31-June.
- 28 Mar 2024 According to a Merck and Co media release, based on positive overall survival results from KEYNOTE-671, company announced that the European Commission (EC) has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adult.